List of Excipients in Branded Drug ZITUVIMET XR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Zydus Pharmaceuticals USA Inc	ZITUVIMET XR	sitagliptin and metformin hydrochloride	70710-1805	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Zydus Pharmaceuticals USA Inc	ZITUVIMET XR	sitagliptin and metformin hydrochloride	70710-1805	CELLULOSE, MICROCRYSTALLINE
Zydus Pharmaceuticals USA Inc	ZITUVIMET XR	sitagliptin and metformin hydrochloride	70710-1805	CROSCARMELLOSE SODIUM

ZITUVIMET XR Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

ZITUVIMET XR is an extended-release fixed-dose combination of sitagliptin and metformin hydrochloride for adults with type 2 diabetes. Its commercial value depends less on novel pharmacology than on reliable control of metformin release, compatibility between two active ingredients, tablet size, dose flexibility, and manufacturing cost. The strongest excipient opportunities are in hydrophilic matrix systems, coating technologies, direct-compression platforms, low-moisture processing, and differentiated dosage forms.

Public product information identifies ZITUVIMET XR as containing sitagliptin and metformin hydrochloride in extended-release tablets. The precise qualitative and quantitative excipient composition should be confirmed against the current FDA-approved labeling, product-specific application records, and regulatory filings before making an investment or licensing decision. [1,2]

What is ZITUVIMET XR and how does its formulation work?

ZITUVIMET XR combines a DPP-4 inhibitor with an extended-release biguanide:

Component	Function	Formulation implication
Sitagliptin	Inhibits DPP-4 and improves glucose-dependent insulin secretion	Requires rapid and consistent drug release
Metformin hydrochloride	Reduces hepatic glucose production and improves insulin sensitivity	Requires controlled release because of high dose and gastrointestinal tolerability
Extended-release tablet platform	Coordinates delivery of both agents	Creates the principal formulation and manufacturing challenge

Metformin is usually the dominant formulation burden. Typical metformin doses are substantially higher by weight than sitagliptin doses, creating large tablets, high compression-force requirements, and potential dissolution variability. The formulation must limit rapid metformin release while maintaining acceptable sitagliptin exposure.

A commercially practical ZITUVIMET XR platform is likely to use one of three architectures:

1. A single hydrophilic matrix tablet containing both active ingredients.
2. A multilayer tablet separating sitagliptin and metformin release zones.
3. A compressed core with a functional film coating that modifies fluid penetration and drug diffusion.

The marketed architecture should be distinguished from these general platform options. Public labeling does not, by itself, establish the detailed manufacturing process, polymer grade, granulation route, or quantitative excipient ratios.

What excipients are most important for ZITUVIMET XR?

The critical excipient classes are release-controlling polymers, compression aids, binders, glidants, lubricants, film-forming agents, and moisture-control components.

Which polymers can control metformin release?

Hydrophilic matrix polymers are the leading platform for metformin extended-release products. Relevant commercial options include:

• Hypromellose, including high-viscosity grades.
• Polyethylene oxide.
• Hydroxypropyl cellulose.
• Carbomer or other swelling polymers in selected designs.
• Combination polymer systems that balance gel strength and erosion.

The polymer must create a reproducible gel barrier after hydration. A low-viscosity grade may produce excessive early release, while an overly strong matrix can generate incomplete release or tablet remnants in the gastrointestinal tract.

Polymer selection creates several commercial opportunities:

• Higher-performance grades that reduce polymer loading.
• Polymer blends that reduce tablet size.
• Robust grades that tolerate changes in compression force.
• Excipient systems compatible with continuous manufacturing.
• Low-peroxide or low-reactive materials that protect sitagliptin stability.

Which fillers and compression aids are commercially relevant?

Metformin hydrochloride has poor flow and high dose loading challenges. Potential fillers and compression aids include:

• Microcrystalline cellulose.
• Lactose-based diluents, subject to compatibility and process requirements.
• Dibasic calcium phosphate.
• Mannitol.
• Coprocessed excipients combining filler and binder functions.

Microcrystalline cellulose is widely used in direct-compression and dry-granulation platforms because it improves compactibility. Dibasic calcium phosphate can improve flow and reduce hygroscopicity but may affect tablet density, disintegration, and tooling wear. Mannitol can support a cleaner taste profile and favorable mouthfeel, although it is less commonly prioritized for a conventional swallowed extended-release tablet.

The commercial objective is not simply to identify the lowest-cost filler. It is to achieve a lower tablet mass without compromising dissolution, content uniformity, hardness, friability, or stability.

Which lubricants and glidants affect manufacturing performance?

Magnesium stearate is a common lubricant, but excessive lubrication can reduce tablet tensile strength and alter matrix hydration. Alternative or complementary materials include:

• Sodium stearyl fumarate.
• Colloidal silicon dioxide.
• Talc, where justified by the formulation and regulatory strategy.
• Low-level stearic acid in selected systems.

For ZITUVIMET XR, lubricant concentration and blending time may influence dissolution because the matrix must hydrate consistently. A short blending process can create poor ejection and sticking; excessive blending can create hydrophobic particle coatings and slow release.

Which coating excipients support product quality?

Film coatings can provide color differentiation, branding, moisture protection, and mechanical protection. Typical film-coating systems may contain:

• Hypromellose or polyvinyl alcohol as the film former.
• Polyethylene glycol or other plasticizers.
• Titanium dioxide or permitted colorants.
• Talc or other anti-tacking agents.
• Opacifiers and pigments.

The coating should not materially interfere with the intended extended-release profile. For moisture-sensitive formulations, a barrier coating can reduce water uptake during storage. However, each added layer raises process complexity, coating time, solvent or water exposure, and cost.

What formulation patents protect ZITUVIMET XR?

Fixed-dose combinations of sitagliptin and metformin have historically been protected through several patent categories:

Patent category	Typical protected subject matter	Commercial relevance
Active-ingredient patents	Sitagliptin composition of matter	Usually the earliest and strongest protection
Combination patents	Sitagliptin plus metformin for diabetes treatment	May cover product use or composition
Extended-release patents	Controlled delivery of metformin or combination products	Can delay or complicate generic substitution
Manufacturing patents	Granulation, compression, coating, or particle-size controls	Often relevant to process design and litigation
Method-of-use patents	Treatment of particular patient groups or dosing regimens	More limited at the pharmacy level
Formulation patents	Specific excipient ratios, layers, release profiles, or dosage strengths	May support lifecycle management

The principal reference product associated with this product class is JANUMET XR, marketed by Merck. Patent and regulatory analysis should separate ZITUVIMET XR from JANUMET XR because a product may enter through an abbreviated or alternative regulatory pathway without copying every formulation element.

The FDA Orange Book should be reviewed for current listed patents, pediatric exclusivity, expiration dates, and any patent-dispute certifications. The Orange Book is the controlling public reference for listed patents tied to approved small-molecule products. [2]

When does ZITUVIMET XR lose exclusivity?

ZITUVIMET XR exclusivity depends on the regulatory pathway and the patents listed for the approved application. FDA small-molecule products may have:

• Five-year new chemical entity exclusivity.
• Three-year exclusivity for certain new clinical investigations.
• Orphan-drug exclusivity, if applicable.
• Pediatric exclusivity, which can add six months to qualifying protections.
• Patent protection extending beyond regulatory exclusivity.

Sitagliptin and metformin are established active ingredients. As a result, the commercial risk is more likely to arise from formulation, combination, method-of-use, and listed-product patents than from new chemical entity protection for the individual compounds.

A competitor seeking approval of a generic version must evaluate Paragraph I through IV certifications for listed patents. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed. The filing can trigger patent litigation and, under applicable conditions, a 30-month stay of approval. [3]

What Paragraph IV challenges and generic entry risks affect ZITUVIMET XR?

Generic-entry risk is driven by five technical questions:

1. Can a competitor reproduce the required sitagliptin and metformin exposure without copying protected claim limitations?
2. Can the applicant design around any polymer, layer, coating, or release-profile claims?
3. Does the reference product require a complex bioequivalence approach?
4. Are multiple strengths eligible for a biowaiver or bracketing strategy?
5. Do listed patents cover the commercial product or only selected formulations and uses?

For an extended-release fixed-dose combination, bioequivalence can be more demanding than for an immediate-release tablet. The applicant may need comparative pharmacokinetic studies under fasting and fed conditions, in vitro dissolution across multiple media, and strength-specific justification.

The principal generic risks are:

• A non-infringing hydrophilic matrix design.
• A bilayer or multiparticulate alternative.
• A different polymer system that produces an equivalent release profile.
• An authorized generic or licensed competitor.
• An ANDA applicant challenging formulation patents through Paragraph IV.

The principal originator defenses are narrow claim drafting around release kinetics, polymer characteristics, tablet architecture, manufacturing parameters, and clinically relevant dosage regimens. Broad functional claims can face enablement, written-description, indefiniteness, or obviousness challenges.

How strong is the ZITUVIMET XR patent estate?

The estate should be rated as moderate rather than automatically strong unless it contains enforceable claims covering the marketed dosage form and a commercially difficult design-around.

Factors supporting patent strength

• Claims tied to a defined extended-release profile.
• Claims covering multiple commercial strengths.
• Narrow excipient ranges that correlate with a measurable performance advantage.
• Manufacturing claims that are difficult to avoid at commercial scale.
• Patents with substantial remaining term.
• FDA-listed patents that correspond directly to the approved product.

Factors weakening patent strength

• Claims focused on routine polymers such as hypromellose without a specific technical limitation.
• Broad combination claims that predate the product.
• Release-profile claims that are difficult to measure consistently.
• Formulation claims with wide prior-art overlap.
• Process claims that can be avoided through dry granulation, wet granulation, or a different coating route.
• Patents expiring close to the expected generic approval date.

A freedom-to-operate analysis should map each claim limitation against at least three design paths: single-matrix, multilayer, and coated-core formulations.

What commercial opportunities exist in the ZITUVIMET XR excipient market?

The highest-value opportunities are not limited to supplying commodity excipients.

Premium matrix-polymer systems

A supplier can position a high-viscosity hypromellose or polyethylene oxide grade around:

• Lower use levels.
• Narrower dissolution variability.
• Better performance across compression forces.
• Reduced tablet size.
• Improved robustness during scale-up.

A successful platform should be supported by comparative dissolution data, tabletability data, and stability studies rather than by general claims about polymer quality.

Coprocessed excipients

Coprocessed filler-binder systems can simplify manufacturing by improving flow, compactibility, and content uniformity. This is relevant where the active load is high and the product must remain within acceptable tablet dimensions.

Potential commercial advantages include reduced unit operations, lower granulation burden, and compatibility with high-speed tablet presses.

Moisture and oxygen management

Sitagliptin-containing formulations may benefit from excipient and packaging systems that limit moisture exposure and reactive impurities. Opportunities include:

• Low-moisture excipient grades.
• Low-peroxide polymers.
• Desiccant-compatible blister systems.
• High-barrier bottles or unit-dose packaging.
• Stability-indicating impurity control.

The strongest commercial case exists where an excipient reduces a measurable degradation pathway or extends shelf life.

Patient-centric dosage forms

ZITUVIMET XR is a swallowed tablet product. Lifecycle opportunities could include:

• Smaller tablets.
• Once-daily regimens where clinically and regulatorily appropriate.
• Modified tablet geometry for easier swallowing.
• Lower-dose strengths for renal-dose flexibility.
• Packaging that improves adherence.
• Alternate dosage forms, subject to the pharmacokinetic and release constraints of metformin.

An orally disintegrating or chewable extended-release product would present substantial technical and regulatory complexity because rapid disintegration is difficult to reconcile with prolonged metformin release.

How does ZITUVIMET XR compare with JANUMET XR?

Criterion	ZITUVIMET XR	JANUMET XR
Active ingredients	Sitagliptin plus metformin hydrochloride	Sitagliptin plus metformin hydrochloride
Therapeutic category	DPP-4 inhibitor and biguanide combination	DPP-4 inhibitor and biguanide combination
Primary formulation challenge	Sustained metformin release with consistent sitagliptin delivery	Same
Commercial differentiation	Price, supply reliability, strengths, contracting, distribution	Established brand and prescriber familiarity
Excipient opportunity	Cost reduction, manufacturing robustness, smaller tablet, differentiated packaging	Lifecycle protection and premium performance
Generic threat	Depends on product-specific patents and approval pathway	Depends on Orange Book patents, litigation, and authorized-generic strategy

The two products compete primarily on price, availability, payer positioning, and confidence in product quality. Excipient differentiation is commercially valuable only if it improves manufacturability, stability, tablet burden, or dissolution robustness.

What FDA regulatory status and Orange Book issues matter?

FDA review should cover:

• Approved dosage strengths.
• Labeling for renal impairment.
• Contraindications and warnings associated with metformin.
• Postmarketing requirements, if any.
• Application type and approval date.
• Orange Book-listed patents and exclusivity.
• Therapeutic-equivalence ratings for competing products.
• Any citizen petitions or product-specific guidance relevant to the formulation.

Metformin products require particular attention to renal function, lactic acidosis risk, gastrointestinal tolerability, and contrast-associated kidney injury. These clinical restrictions influence demand for lower strengths and may create lifecycle opportunities around dose flexibility. [1,4]

What manufacturing and intellectual-property barriers exist?

The main manufacturing barriers are:

• Uniform distribution of the low-dose sitagliptin component within a high-dose metformin matrix.
• Consistent matrix hydration and erosion.
• Tablet compression without capping or lamination.
• Control of blend segregation.
• Coating uniformity across large tablets.
• Dissolution reproducibility after scale-up.
• Stability under moisture and temperature stress.

The main IP barriers are:

• Patents on extended-release combination compositions.
• Claims covering specific dosage strengths.
• Claims tied to release rates or dissolution windows.
• Process claims involving granulation and compression.
• Method-of-use claims for dosing in renal impairment or selected patient populations.

A design-around strategy should prioritize a different claim architecture, not merely a different supplier of the same excipient. Switching from one hypromellose supplier to another may not avoid a claim directed to the polymer class or functional release profile.

What revenue exposure and market opportunities exist?

ZITUVIMET XR participates in a large type 2 diabetes market with mature metformin demand and established use of sitagliptin combinations. The revenue opportunity is strongest where the product can capture:

• Patients requiring dual therapy.
• Patients seeking a lower-cost alternative to branded sitagliptin combinations.
• Payers demanding generic or multisource pricing.
• Prescribers seeking a familiar DPP-4 inhibitor without insulin-associated hypoglycemia risk.
• Markets where fixed-dose combination adherence is valued.

Revenue exposure is also significant because the product competes against multiple metformin combinations, sulfonylureas, GLP-1 receptor agonists, SGLT2 inhibitors, and insulin therapies. Price erosion can be rapid after multiple generic entrants. A differentiated excipient platform can protect margins only if it supports a defensible formulation, reliable supply, or lower cost of goods.

Key Takeaways

• ZITUVIMET XR is a sitagliptin and metformin hydrochloride extended-release combination.
• Metformin dose loading and controlled release are the central formulation problems.
• Hydrophilic matrix polymers, coprocessed compression aids, lubrication control, and moisture protection are the highest-value excipient areas.
• The strongest commercial excipient propositions reduce tablet size, improve dissolution robustness, lower manufacturing cost, or extend stability.
• Patent risk is likely to center on formulation, combination, process, and method-of-use claims rather than only on the active ingredients.
• Paragraph IV challenges can target release architecture, excipient ranges, manufacturing methods, and listed formulation patents.
• The FDA Orange Book and current approved labeling are essential for confirming patents, exclusivity, strengths, and regulatory status.
• A credible design-around strategy should change the protected formulation architecture, not merely the excipient vendor.
• Commercial success depends on price, payer access, supply reliability, tablet burden, and therapeutic-equivalence positioning.

FAQs

Can hypromellose be replaced in a ZITUVIMET XR generic?

Yes. A competitor may evaluate polyethylene oxide, hydroxypropyl cellulose, carbomer, or polymer blends, provided the alternative achieves bioequivalence, dissolution comparability, stability, and acceptable manufacturability.

Does a smaller ZITUVIMET XR tablet create a patent opportunity?

Potentially. A smaller tablet can support claims directed to polymer loading, tablet density, compression characteristics, or release performance. Patent strength depends on whether the reduced size is linked to a non-obvious technical result.

Are metformin excipient patents commercially valuable after active-ingredient patents expire?

Yes. Formulation and process patents can remain commercially relevant after active-ingredient protection ends. Their value declines if competitors can achieve equivalent release using routine design-around approaches.

Is a bilayer tablet preferable to a single-matrix tablet?

Not universally. A bilayer structure can separate sitagliptin from metformin and improve release control, but it increases equipment requirements, process controls, and scale-up risk.

What is the best excipient licensing strategy for ZITUVIMET XR?

The strongest strategy is to license a validated platform with comparative dissolution, tabletability, stability, scale-up, and regulatory-support data. A commodity excipient supply agreement generally provides less differentiation than a platform license tied to measurable formulation performance.

References

1. U.S. Food and Drug Administration. (n.d.). ZITUVIMET XR prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (2017). Guidance for industry: 180-day exclusivity: Questions and answers.

4. U.S. Food and Drug Administration. (2016). Guidance for industry: Metformin hydrochloride drug products, bioequivalence recommendations.